Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary

JOURNAL OF ONCOLOGY PRACTICE

AMER SOC CLINICAL ONCOLOGY

1. Bristol-Myers Squibb
2. Merck
3. AstraZeneca
4. Incyte
5. Five Prime Therapeutics
6. Janssen Oncology
7. F Hoffman-La Roche
8. Seattle Genetics
9. Pfizer
10. Agensys
11. Corvus Pharmaceuticals
12. Trillium Therapeutics
13. Novartis